- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02206841
Establishment of NAFLD Cohort and Development of Fibrosis Markers (NAFLD)
November 20, 2023 updated by: Won Kim, Seoul National University Boramae Hospital
Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
- Acoustic radiation force impulse elastography and transient elastography
- Liver tissue (frozen tissue, paraffin block)
- Whole blood, Serum
- Fat amount ratio CT (Visceral adipose tissue, Subcutaneous adipose tissue amount)
- Body composition analyzer (InBody scale):Total fat/muscle mass and appendicular skeletal muscle mass
- Pulmonary function test with post-bronchodilator response and DLCo
- EKG, EchoCG, Heart CT (Coronary calcium score), and Pusle wave velocity (AI index, arterial stiffness)
- Brain MRI or CT
- Upper esophagogastroscopy and colonoscopy
- Berlin score questionnaire and Polysomnography
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Won Kim, MD,PhD
- Phone Number: 8228702233
- Email: drwon1@snu.ac.kr
Study Contact Backup
- Name: Saekyung Joo, MD
- Phone Number: 821089619285
- Email: joo.sammy@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 156-707
- Recruiting
- Seoul Metropolitan Government Seoul National University
-
Contact:
- Won Kim, MD, PhD
- Phone Number: 8228702233
- Email: drwon1@snu.ac.kr
-
Principal Investigator:
- Won Kim, MD,PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Non-alcoholic fatty liver disease
Description
Inclusion Criteria:
- Patients with histologically confirmed fatty liver disease
- Patients with radiologically confirmed fatty liver disease
Exclusion Criteria:
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NAFLD
Patients with suspected nonalcoholic fatty liver disease will be screened.
Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained.
In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed.
A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis.
Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study.
Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
|
Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
Transient elastography will be performed for evaluate fibrosis of liver.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
histologic steatosis and fibrosis grade
Time Frame: baseline
|
We will evaluate fibrosis using laboratory examination, radiologic evaluation and liver tissue pathology.
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of markers for hepatic fibrosis progression
Time Frame: baseline and every 6 months (up to 1year)
|
We will analysis and development fibrosis markers by obtained blood sample and liver tissue,
|
baseline and every 6 months (up to 1year)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Won Kim, Professor, SMG-SNU Boramae Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Koo BK, Joo SK, Kim D, Bae JM, Park JH, Kim JH, Kim W. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018 Jun;33(6):1277-1285. doi: 10.1111/jgh.14056. Epub 2018 Feb 26.
- Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, Chang MS, Kim JH, Lee J, Jeong WI, Kim W. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2018 Apr;38(4):695-705. doi: 10.1111/liv.13587. Epub 2017 Sep 30.
- Joo SK, Kim W, Kim D, Kim JH, Oh S, Lee KL, Chang MS, Jung YJ, So YH, Lee MS, Bae JM, Kim BG. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int. 2018 Feb;38(2):331-341. doi: 10.1111/liv.13549. Epub 2017 Sep 5.
- Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A. Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis. Clin Gastroenterol Hepatol. 2018 Jan;16(1):123-131.e1. doi: 10.1016/j.cgh.2017.08.014. Epub 2017 Aug 18.
- Kim JY, Park KJ, Hwang JY, Kim GH, Lee D, Lee YJ, Song EH, Yoo MG, Kim BJ, Suh YH, Roh GS, Gao B, Kim W, Kim WH. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. J Hepatol. 2017 Aug;67(2):349-359. doi: 10.1016/j.jhep.2017.03.023. Epub 2017 Mar 30.
- Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017 Jan;66(1):123-131. doi: 10.1016/j.jhep.2016.08.019. Epub 2016 Sep 4.
- Lee MS, Bae JM, Joo SK, Woo H, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One. 2017 Nov 27;12(11):e0188321. doi: 10.1371/journal.pone.0188321. eCollection 2017. Erratum In: PLoS One. 2018 Jun 26;13(6):e0200055.
- Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2022 Apr;55(8):994-1007. doi: 10.1111/apt.16766. Epub 2022 Jan 9.
- Kim D, Kim W, Joo SK, Han J, Kim JH, Harrison SA, Younossi ZM, Ahmed A. Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. J Gastroenterol. 2020 Mar;55(3):330-341. doi: 10.1007/s00535-019-01628-z. Epub 2019 Sep 18.
- Kim D, Kim W, Joo SK, Kim JH, Harrison SA, Younossi ZM, Ahmed A. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int. 2019 Feb;39(2):332-341. doi: 10.1111/liv.13983. Epub 2018 Oct 27.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2030
Study Registration Dates
First Submitted
July 28, 2014
First Submitted That Met QC Criteria
July 30, 2014
First Posted (Estimated)
August 1, 2014
Study Record Updates
Last Update Posted (Actual)
November 21, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NAFLD_cohort
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibrosis of Liver
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Tîrgu Mureș Emergency Clinical County Hospital,...CompletedTo Generate Microbial Hypotheses Putatively Responsible for the Onset of Liver Fibrosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
E-ScopicsNot yet recruitingLiver Diseases | Liver Cirrhosis | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Steatosis of Liver
-
University of OxfordAssistance Publique - Hôpitaux de Paris; University of Nottingham; Novartis; Pf... and other collaboratorsRecruitingNAFLD | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | NASH | Steatosis of LiverFinland, United Kingdom, Greece, Germany, Sweden, Spain, Italy, Switzerland, United States, France
-
King's College LondonKing's College Hospital NHS TrustCompletedCirrhosis of the LiverUnited Kingdom
-
Assiut UniversityUnknownCT Portography Grading of Liver Cirrhosis
-
Alentis Therapeutics AGRecruitingLiver Cirrhosis | Advanced Liver FibrosisGermany, Romania, Slovakia
-
Bristol-Myers SquibbCompleted
-
University Hospital, AngersRecruitingScreening | Advanced Liver FibrosisFrance
Clinical Trials on Liver biopsy
-
Nottingham University Hospitals NHS TrustRecruitingLiver Diseases | Liver FibrosisUnited Kingdom
-
The Cleveland ClinicCompleted
-
Rutgers, The State University of New JerseyTerminatedLiver Disease | Brain DeathUnited States
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingLiver CirrhosisIndia
-
Brigham and Women's HospitalWithdrawn
-
Asian Institute of Gastroenterology, IndiaCompletedNAFLD | Alcoholic HepatitisIndia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingLiver and Intrahepatic Bile Duct CarcinomaUnited States
-
Hospital Clinico Universitario de SantiagoCompletedLiver DiseasesSpain
-
Mayo ClinicCompleted
-
St. Louis UniversityBoston University; University College, London; University of Massachusetts, Worcester and other collaboratorsActive, not recruiting